ClinicalTrials.gg

Program

BCMA-CD19 Compound CAR T Cells

Its studies are mostly in Multiple Myeloma · Purpura, Thrombocytopenic, Idiopathic · Lupus Erythematosus, Systemic, led by iCell Gene Therapeutics.

Furthest: phase 1, since Nov 11, 20193 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
iCell Gene Therapeutics33 open or runningphase 1since Nov 11, 2019Nov 11, 2019none ahead

Also a collaborator on its studies: iCAR Bio Therapeutics and iCell ImmunityX(Hangzhou).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2019First study: phase 1 study in Multiple MyelomaFirst studyNCT04162353 · 12 planned · China
  2. Jul 23, 2022Phase 1 study in RecurrenceNCT05474885 · 15 planned · China
  3. Jan 8, 2025Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT06787989 · 20 planned · China

TargetBeta

“A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06787989Purpura, Thrombocytopenic, Idiopathic · China1RecruitingAug 202620
NCT05474885Recurrence · China1RecruitingApr 30, 202515
NCT04162353Multiple Myeloma · China1RecruitingJul 202612

How it is read

Names in the registry

  • “BCMA-CD19 cCAR T cells”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.